sponsor symposia

30 November, 2018 (Friday)

12:45-13:45 Room 201ABC, 2F

Lunch Symposium 1 - Time for new treatment paradigm in milder asthma? (AstraZeneca Taiwan)
Chair: Diahn-Warng Perng (Taiwan)

No. Topic
LS01-1
Overuse of SABA and underuse of ICS in milder asthma - the asthma paradox
Eric Bateman (South Africa)
LS01-2 Challenges in the treatment of patients with milder asthma in Taiwan and Asia
Ping-Hung Kuo (Taiwan)
12:45-13:45 Room 201DEF, 2F

Lunch Symposium 2 - Progressive pulmonary fibrosis: current and future perspectives (Boehringer Ingelheim International GmbH)
Chair: Meng-Chih Lin (Taiwan)
Chair: Athol Wells (United Kingdom)

No. Topic
LS02-1 Diagnosis of IPF: guidelines and practice
Athol Wells (United Kingdom)
LS02-2 Optimal use of antifibrotic therapies in IPF
Martin Kolb (Canada)
LS02-3 Ongoing research in progressive fibrosing ILDs
Luca Richeldi (Italy)
12:45-13:45 Room VIP, 4F

Lunch Symposium 3 - REALISEing the Power of Transformative RWEs (Mundipharma)
Chair: Hao-Chien Wang (Taiwan)

No. Topic
LS03-1
Tailoring asthma management to your patients: Realizations from REALISE ASIA
Aileen David Wang (Philippines)
LS03-2 What is TRANSFORMing Asthma Practice: DPI, pMDI or upcoming Breath Triggered Inhalers ?
Chin Kook Rhee (Korea)
LS03-3 How will exacerbation rates from RWEs impact your practice?
Dato Abdul Razak Abdul Muttalif (Malaysia)
12:45-13:45 Room 103, 1F

Lunch Symposium 4 - NIV management for COPD (ResMed)
Chair: Naricha Chirakalwasan (Thailand)
Chair: Ning-Hung Chen (Taiwan)

No. Topic
LS04-1 Overview of NIV management in Asia
Ning-Hung Chen (Taiwan)
LS04-2 From Hospital to Home - NIV Management for COPD Patient
Mark William Elliott (UK)
12:45-13:45 Room 105, 1F

Lunch Symposium 5 - Optimize the clinical benefit of chemotherapy for NSCLC (Eli Lilly)
Chair: Chong-Jen Yu (Taiwan)
Chair: Jin-Yuan Shih (Taiwan)

No. Topic
LS05-1 Alimta real world data from Taiwan NHIRD
Te-Chun Hsia (Taiwan)
LS05-2 The role of antiangiogenic drug in hard to treat NSCLC
Egbert Smit (Netherlands)
17:45-18:45 Room 103, 1F

Evening Symposium 1 - The Unprecedented Overall Survival Benefits for advanced NSCLC by Anti-PD-1 in 1L (MSD Taiwan)
Chair: Chong-Jen Yu (Taiwan)

No. Topic
ES01-1 The Unprecedented Overall Survival Benefits for advanced NSCLC by Anti-PD-1 in 1L
Steven Kao (Australia)
ES01-2 TBC
TBC

 

1 December, 2018 (Saturday)

12:45-13:45 Room 201ABC, 2F

Lunch Symposium 6 - Focus on Reducing OCS in Severe Asthma - the Why and the How? (AstraZeneca Taiwan)
Chair: Sang-Heon Kim (Korea)

No. Topic
LS06-1 Insights into the cumulative burden of OCS exposure
Sang-Heon Kim (Korea)
LS06-2 Understanding the patients experience and the impact of OCS use
V McDonald (Australia)
LS06-3 Strategies to reduce OCS use and exposure in the era of biologic agents
J Upham (Australia)
12:45-13:45 Room 201DEF, 2F

Lunch Symposium 7 - Breaking paradigms : Treatment evolution in asthma (GSK)
Chair: Shu-Min Lin (Taiwan)

No. Topic
LS07-1 The ICS/LABA experience : any new update?
Norbert Berend (Australia)
LS07-2 Challenges in severe asthma : the role of new biologics
Frank Albers (USA)
12:45-13:45 Room VIP, 4F

Lunch Symposium 8 - COPD (Chiesi and OEP)
Chair: Chong-Jen Yu (Taiwan)

No. Topic
LS08-1 Topic related to small airways dysfunction in COPD
Kang-Yun Lee (Taiwan)
LS08-2 Extra-fine benefit in COPD
Dave Singh (UK)
12:45-13:45 Room 102, 1F

Lunch Symposium 9 - Practical, personalized care: A tailored approach to management of COPD (Boehringer Ingelheim International GmbH)
Chair: Diahn-Warng Perng (Taiwan)
Chair: David M.G. Halpin (UK)

No. Topic
LS09-1 COPD care in Asia: Current perspectives, future directions
Diahn-Warng Perng (Taiwan)
LS09-2 Building on strong foundations: The importance of inhaler choice in COPD
Omar Usmani (UK)
LS09-3 Mapping the role of ICS: Building on the latest insights in COPD
Marc Miravitlles (Spain)
LS09-4 Steering the course: What outcomes matter most for our patients?
David M.G. Halpin (UK)
12:45-13:45 Room 103, 1F

Lunch Symposium 10 - Recent advances in preventing exacerbations of COPD (Novartis)
Chair: Wu-Huei Hsu (Taiwan)
Chair: Horng-Chyuan Lin (Taiwan)

No. Topic
LS10-1 The Science of COPD Exacerbations: Time to take it personally
Jadwiga Wisia Wedzicha (UK)
LS10-2 Topic Preventing COPD exacerbations: Pharmacotherapeutic approaches in 2018
Kenneth R. Chapman (Canada)
12:45-13:45 Room 105, 1F

Lunch Symposium 11 - Future ALK NSCLC treatment landscape (Novartis)
Chair: Jin-Yuan Shih (Taiwan)

No. Topic
LS11-1 The role of NGS in determining sequential treatment for ALK-positive NSCLC
David Planchard (France)
LS11-2 Updated treatment strategy for BRAF mutant NSCLC and real world experience from France
David Planchard (France)
LS11-3 Classification and management of neuroedocrine tumor in lung
Te-Chun Hsia (Taiwan)
17:45-18:45 Room 201ABC, 2F

Evening Symposium 2 - Asthma (OEP)
Chair: Jubert Benedicto (Philippine)

No. Topic
ES02-1 Topic related to small airways dysfunction in Asthma (TBC)
Diahn-Warng Perng (Taiwan)
ES02-2 Real-life study of Extra-fine formulation in Asthma
David Price (UK)
17:45-18:45 Room 201DEF, 2F

Evening Symposium 3 - Individualizing the therapeutic strategy in COPD (GSK)
Chair: Meng-Chih Lin (Taiwan)

No. Topic
ES03-1 COPD facts and gaps in Asia Pacific          
Horng-Chyuan Lin (Taiwan)
ES03-2 The role of the Ellipta portfolio
Paul Jones (UK)
17:45-18:45 Room VIP, 4F

Evening Symposium 4 - Roche satellite symposium of Cancer ImmunoTherapy in Lung Cancer (Roche)
Chair: Gee-Chen Chang (Taiwan)

No. Topic
ES04-1 Activate the POWER- clinical advances of atezolizumab in lung cancer
Leora Horn (USA)
ES04-2 Cancer Immunotherapy in EGFR+ patients
Shih-Hsin Hsiao (Taiwan)
17:45-18:45 Room 103, 1F

Evening Symposium 5 - The asthma patient journey: What more can be done? (Novartis)
Chair: Kang-Yun Lee (Taiwan)
Chair: Shih-Lung Cheng (Taiwan) 

No. Topic
ES05-1 Phenotype/endotype in severe asthma patients
Kian Fan Chung (UK)
ES05-2 Current options for severe asthma treatment and what’s on the horizon?
Po-Jui Chang (Taiwan)
17:45-18:45 Room 105, 1F

Evening Symposium 6 - A Paradigm shift in the treatment of locally advanced and advanced NSCLC (AstraZeneca Taiwan)
Chair: James Yang (Taiwan)

No. Topic
ES06-1 Evolving decisions and best practices in the management of EGFR M+ NSCLC
Suresh S. Ramalingam (USA)
ES06-2 Incoporating multimodality strategy in locally advanced NSCLC
Chao-Chi Ho (Taiwan)